Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) has announced the release of topline data from its Phase 1 trial of treprostinil palmitil inhalation powder (TPIP) on February 19, 2021. This trial targets the treatment of pulmonary arterial hypertension (PAH) and rare pulmonary disorders. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the findings and provide updates. TPIP is a unique formulation developed in-house, showcasing Insmed's commitment to addressing unmet medical needs.

Positive

• Upcoming topline data release from Phase 1 trial of TPIP on February 19, 2021.
• Potential differentiation of TPIP for treating pulmonary arterial hypertension and rare pulmonary disorders.
• Insmed's continuing commitment to pipeline development for serious and rare diseases.

Negative

• None.

BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy volunteer trial of treprostinil palmitil inhalation powder (TPIP) on Friday, February 19, 2021.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Friday, February 19, 2021 to discuss findings and provide an update.

Shareholders and other interested parties may participate in the conference call by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and referencing conference ID number 1963113. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through March 21, 2021 by dialing (800) 585-8367 (domestic) or (416) 621-4642 (international) and referencing conference ID number 1963113. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Developed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being evaluated for the treatment of patients with pulmonary arterial hypertension (PAH) and other rare and serious pulmonary disorders. TPIP is administered in a capsule-based inhalation device.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States and the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact: 

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
eleanor.barisser@insmed.com 

Media:

Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-conference-call-to-discuss-topline-data-from-treprostinil-palmitil-inhalation-powder-phase-1-study-301228316.html

SOURCE Insmed Incorporated

FAQ

What is the purpose of the Phase 1 trial for TPIP?

The Phase 1 trial aims to evaluate the safety and pharmacokinetics of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers, with the intent to treat pulmonary arterial hypertension and other rare pulmonary disorders.

When will the topline data for TPIP be released?

The topline data from the Phase 1 trial of TPIP will be released on February 19, 2021.

How can investors participate in the conference call?

Investors can participate in the conference call by dialing (833) 340-0284 (domestic) or (236) 712-2425 (international) and using conference ID number 1963113.

What is Insmed's focus in developing TPIP?

Insmed focuses on developing TPIP as a treatment option for patients with pulmonary arterial hypertension (PAH) and other serious pulmonary disorders, providing a potentially differentiated therapeutic solution.

Where can I find the webcast of the conference call?

The conference call will be webcast live on Insmed's website, and a replay will be available for approximately 90 days in the Investor Relations section.